Wang Kun, Li Hua-Long, Bei Wei-Jie, Guo Xiao-Sheng, Chen Shi-Qun, Islam Sheikh Mohammed Shariful, Chen Ji-Yan, Liu Yong, Tan Ning
Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Key Laboratory of Coronary Disease, Guangdong General Hospital, Guangdong Academy of Medical Sciences.
School of Medicine, South China University of Technology, Guangzhou, People's Republic of China.
Ther Clin Risk Manag. 2017 Jul 19;13:887-895. doi: 10.2147/TCRM.S137654. eCollection 2017.
Left ventricular ejection fraction (LVEF) is the most widely used parameter to evaluate the cardiac function in patients with heart failure (HF). However, the association between LVEF and contrast-induced nephropathy (CIN) is still controversial. Therefore, the aim of this study is to evaluate the association of LVEF with CIN and long-term mortality following coronary angiography (CAG) or intervention in patients with HF.
We analyzed 1,647 patients with HF (New York Heart Association [NYHA] or Killip class >1) undergoing CAG or intervention, including 207 (12.57%) patients with reduced LVEF (HFrEF), 238 (14.45%) with mid-range LVEF (HFmrEF) and 1,202 (72.98%) with preserved LVEF (HFpEF). CIN was defined as an absolute increase of ≥0.5 mg/dL or a relative increase of ≥25% from baseline serum creatinine within 48-72 h after contrast medium exposure. Multivariable logistic regression and Cox proportional hazards regression analyses were performed to identify the association between LVEF, CIN and long-term mortality, respectively.
Overall, 225 patients (13.7%) developed CIN. Individuals with lower LVEF were more likely to develop CIN (HFrEF, HFmrEF and HFpEF: 18.4%, 21.8% and 11.2%, respectively; <0.001), but without a significant trend after adjusting for the confounding factors (HFrEF vs HFpEF: odds ratio [OR] =1.01; HFmrEF vs HFpEF: OR =1.31; all >0.05). However, advanced HF (NYHA class >2 or Killip class >1) was an independent predictor of CIN (adjusted OR =1.54, 95% confidence interval [CI], 1.07-2.22; =0.019). During the mean follow-up of 2.3 years, reduced LVEF (HFrEF group) was significantly associated with increased mortality (HFrEF vs HFpEF: adjusted hazard ratio =2.88, 95% CI, 1.77-4.69; <0.001).
In patients with HF undergoing CAG or intervention, not worsened LVEF but advanced HF was associated with an increased risk of CIN. In addition, reduced LVEF was an independent predictor of long-term mortality following cardiac catheterization.
左心室射血分数(LVEF)是评估心力衰竭(HF)患者心功能最常用的参数。然而,LVEF与对比剂诱导的肾病(CIN)之间的关联仍存在争议。因此,本研究旨在评估HF患者冠状动脉造影(CAG)或介入治疗后LVEF与CIN及长期死亡率的关联。
我们分析了1647例接受CAG或介入治疗的HF患者(纽约心脏协会[NYHA]或Killip分级>1),包括207例(12.57%)LVEF降低的患者(射血分数降低的心力衰竭[HFrEF])、238例(14.45%)LVEF中等的患者(射血分数中等的心力衰竭[HFmrEF])和1202例(72.98%)LVEF保留的患者(射血分数保留的心力衰竭[HFpEF])。CIN定义为造影剂暴露后48 - 72小时内血清肌酐较基线绝对增加≥0.5mg/dL或相对增加≥25%。分别进行多变量逻辑回归和Cox比例风险回归分析,以确定LVEF、CIN与长期死亡率之间的关联。
总体而言,225例患者(13.7%)发生了CIN。LVEF较低的个体更易发生CIN(HFrEF、HFmrEF和HFpEF分别为18.4%、21.8%和11.2%;P<0.001),但在调整混杂因素后无显著趋势(HFrEF与HFpEF:比值比[OR]=1.01;HFmrEF与HFpEF:OR =1.31;均>未提及具体数值,推测为0.05)。然而,晚期HF(NYHA分级>2或Killip分级>1)是CIN的独立预测因素(调整后OR =1.54,95%置信区间[CI],1.07 - 2.22;P =0.019)。在平均2.3年的随访期间,LVEF降低(HFrEF组)与死亡率增加显著相关(HFrEF与HFpEF:调整后风险比=2.88,95%CI,1.77 - 4.69;P <0.001)。
在接受CAG或介入治疗的HF患者中,与CIN风险增加相关的不是LVEF恶化而是晚期HF。此外,LVEF降低是心脏导管检查后长期死亡率的独立预测因素。